The FDA scheduled a panel meeting to discuss and vote on the premarket approval of Ocular Therapeutix's ReSure Sealant, a drug-delivering hydrogel device designed to protect the eye after cataract surgery. It would be the only FDA-approved sealant for ophthalmic use if it passes the Opthalmic Devices Panel scheduled for Sept. 19. "Our goal was to fill a void in the marketplace for a device that can enhance post-operative care of cataract patients by providing greater certainty of wound closure," Ocular CEO Amar Sawhney said. Release